Alexandria Phan, MD

Alexandria Phan, MD, the director of GI Medical Oncology at Houston Methodist, discusses the importance of the approval of lanreotide for unresectable, well or moderately differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

CLARINET was the largest study to show benefit with lanreotide for the treatment of patients with unresectable, well or moderately differentiated, locally advanced or metastatic GEP-NETs.

The study reinforced what was previously known about somatostatin analogues.

Lanreotide is generally well tolerated. No abnormal side effects were observed in CLARINET.

Videos

Alexandria Phan, MD, discusses the importance of the approval of lanreotide for unresectable, well or moderately differentiated, locally advanced or metastatic GEP-NETs.

Alexandria Phan, MD | Authors

Articles

The Importance of the Approval of Lanreotide and its Known Side Effects